Young people with a rare condition called Juvenile Idiopathic Arthritis (JIA) are taking part in clinical research to better ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it.

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that affects children and is characterized by arthritis lasting for more than six weeks with an onset before the age of 16.

According to the National Institutes of Health and previous research, juvenile idiopathic arthritis affects about 16 to 150 per 100,000 children in North America, causing chronic inflammation ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

Juvenile Idiopathic Arthritis (JIA) is a chronic inflammatory condition that affects children and can lead to various complications, including uveitis, which is inflammation of the eye.

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The consensus based term for a rheumatic joint disorder in childhood is “juvenile idiopathic arthritis (JIA)”, and not “juvenile rheumatic coxitis.” [note: the author points out a mistake ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...